EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year on the market. | After repeatedly wowing investors, Roche’s star eye med ...

Red light therapy is increasingly viewed as a promising treatment for wrinkles, acne, psoriasis, scars and sun-damaged skin, and as a supportive therapy for some kinds of cancer. But does red light ...

These are the best vitamins and supplements for eye health, which are great for supporting your vision and helping you take ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced substantial progress in 2024, with three new investments, several follow-on ...

Eye Care Supplement MarketThe global eye care supplement market is on the cusp of significant expansion, with leading market analysis authority Future Market Insights (FMI) predicting a valuation of ...

Opthea Ltd shares have reached a remarkable 52-week high, touching $5.48 amidst a period of significant growth. With a market capitalization of nearly $798 million, the company has caught analysts' ...

What is red light therapy? Treatment with red light therapy involves exposure to red light at a very low dose in a hospital or clinic. It’s also called low-power laser therapy, soft laser therapy, ...

H.C. Wainwright initiated coverage on Surrozen Inc. (NASDAQ:SRZN) with a Buy rating and established a price target of $32.00. The clinical-stage biotechnology company, currently valued at ...